Morgan Stanley Pro Qr Therapeutics N.V. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Morgan Stanley holds 2,901,202 shares of PRQR stock, worth $6.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,901,202

Previous 3,083,490 5.91%

Holding current value

$6.35 Million

Previous $6.29 Million 2.69%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.89 - $2.48 $344,524 - $452,074	-182,288 Reduced 5.91%	2,901,202 $6.12 Million
Q2 2025 Aug 15, 2025	BUY	$1.12 - $2.16 $1.9 Million - $3.67 Million	1,699,997 Added 122.88%	3,083,490 $6.29 Million
Q1 2025 May 15, 2025	BUY	$1.33 - $2.77 $1.19 Million - $2.49 Million	897,508 Added 184.68%	1,383,493 $1.84 Million
Q4 2024 Feb 14, 2025	BUY	$1.81 - $4.49 $382,878 - $949,792	211,535 Added 77.08%	485,985 $1.33 Million
Q3 2024 May 14, 2025	BUY	$1.64 - $2.24 $322,273 - $440,177	196,508 Added 252.12%	274,450 $499,000
Q3 2024 Nov 14, 2024	BUY	$1.64 - $2.24 $322,273 - $440,177	196,508 Added 252.12%	274,450 $499,000
Q2 2024 May 14, 2025	SELL	$1.65 - $2.39 $673,270 - $975,222	-408,043 Reduced 83.96%	77,942 $129,000
Q2 2024 Oct 17, 2024	BUY	$1.65 - $2.39 $17,079 - $24,738	10,351 Added 15.31%	77,942 $129,000
Q2 2024 Aug 14, 2024	BUY	$1.65 - $2.39 $17,079 - $24,738	10,351 Added 15.31%	77,942 $129,000
Q1 2024 Oct 17, 2024	SELL	$1.89 - $2.85 $19,563 - $29,500	-10,351 Reduced 13.28%	67,591 $154,000
Q1 2024 Aug 16, 2024	SELL	$1.89 - $2.85 $87,166 - $131,442	-46,120 Reduced 40.56%	67,591 $154,000
Q1 2024 May 15, 2024	SELL	$1.89 - $2.85 $87,166 - $131,442	-46,120 Reduced 40.56%	67,591 $154,000
Q4 2023 Aug 16, 2024	BUY	$1.15 - $2.21 $41,134 - $79,049	35,769 Added 45.89%	113,711 $225,000
Q4 2023 Feb 13, 2024	SELL	$1.15 - $2.21 $263,634 - $506,635	-229,247 Reduced 66.84%	113,711 $225,000
Q3 2023 Nov 15, 2023	SELL	$1.3 - $1.77 $198,325 - $270,027	-152,558 Reduced 30.79%	342,958 $445,000
Q2 2023 Aug 14, 2023	SELL	$1.62 - $2.32 $248,414 - $355,753	-153,342 Reduced 23.63%	495,516 $802,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $537,713 - $988,961	270,208 Added 71.36%	648,858 $1.38 Million
Q4 2022 Feb 14, 2023	SELL	$0.8 - $3.7 $79,250 - $366,533	-99,063 Reduced 20.74%	378,650 $1.4 Million
Q3 2022 Nov 14, 2022	BUY	$0.74 - $0.89 $58,399 - $70,237	78,918 Added 19.79%	477,713 $355,000
Q2 2022 Oct 27, 2022	BUY	$0.56 - $1.0 $110,258 - $196,891	196,891 Added 97.52%	398,795 $311,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $110,258 - $196,891	196,891 Added 97.52%	398,795 $311,000
Q1 2022 Oct 27, 2022	SELL	$0.9 - $8.39 $177,201 - $1.65 Million	-196,891 Reduced 49.37%	201,904 $183,000
Q1 2022 May 13, 2022	BUY	$0.9 - $8.39 $148,754 - $1.39 Million	165,283 Added 451.33%	201,904 $183,000
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $489,874 - $628,349	-74,449 Reduced 67.03%	36,621 $293,000
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $573,121 - $940,762	111,070 New	111,070 $930,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

38.3M

Call Options Held

Put Options Held

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $156M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account